Blackford Analysis is pleased to announce today that it has signed an Alliance Partner Agreement with Resonance Health.
Blackford provides a single platform that enables healthcare providers to quickly access and manage medical image analysis applications and AI algorithms that add clinical value. The platform allows healthcare providers to use imaging information efficiently and reduce the cost of care while improving diagnostic confidence and patient outcomes. The collaboration allows all of Blackford’s current and future customers access to Resonance Health products.
The Blackford Platform integrates directly with PACs systems used by hospitals, including those provided by channel partners such as Intelerad and eRAD. The Resonance Health product FerriSmart® will now integrate seamlessly with the Blackford Platform, allowing for easy access from existing clinical workflows to improve diagnostic confidence, reduce the cost of care, and add clinical value.
This agreement gives Blackford the right to promote, market, sell, distribute, and license FerriSmart® directly and/or via resellers. FerriScan® and HepaFat-Scan® are also listed in the agreement and Resonance Health may subsequently authorize Blackford to integrate these with, or offer these in connection with, the Blackford platform. Work will now commence to integrate FerriSmart® with the Blackford platform. Blackford provides services in the United States, Canada, UK, Australia, and New Zealand.
Blackford CEO, Ben Panter said this of the alliance: “We look forward to working with Resonance Health to provide our customers and channel partners quick access to FerriSmart through our single platform, to help provide additional clinical value for patients.”
Resonance Health’s CEO, Alison Laws commented: “Integration into existing radiology workflows will mean seamless accessibility for our products across a new customer base, allowing us to provide future customers with the highest quality data for use in the clinical management of patients. We are very pleased to be working with Blackford to deliver our services as part of the Blackford platform”.
About Resonance Health
Resonance Health is an Australian healthcare company specializing in the development and delivery of non-invasive medical imaging software and services. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing highest quality quantitative measurements essential in the management of particular diseases. Resonance Health products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical companies in their clinical trials. Resonance’s flagship product FerriScan® is the global gold-standard for liver iron concentration quantification and has become established in many international ‘Standards of Care’ for Thalassemia and Sickle Cell Disease. FerriScan®’s proprietary technology recently has been applied in training neural networks to develop our new product FerriSmart®, the world’s first and only regulatory-cleared Artificial Intelligence tool for the quantification of liver iron concentration.